Czerney Kevin 4

What Happened
Kevin Czerney, Vice President and Chief Accounting Officer of DENTSPLY SIRONA (XRAY), was granted equity awards on March 4, 2026: 13,690 restricted stock units (RSUs) and 10,400 derivative awards (stock-option-style grant). Both grants are reported as acquisitions (transaction code A) with a grant price of $0.00 (no cash paid by the insider at grant).

Key Details

• Transaction date: 2026-03-04; Form 4 filed 2026-03-06 (appears timely).
• RSUs: 13,690 units granted (Footnote F1). Vesting: one-third annually over three years, finishing March 4, 2029.
• Derivative award: 10,400 units (Footnote F2). These options vest one-third annually over three years (ending March 4, 2029) with an exercise price equal to 110% of the closing stock price on the grant date.
• Reported price/value at grant: $0.00 (standard for equity awards reported as grants).
• Shares owned after the transaction: not specified in the information provided.
• Filing timeliness: filed two days after the reported date—within the typical Form 4 reporting window.

Context

• These were compensation grants, not open-market purchases or sales; they do not indicate an immediate cash outlay by the insider nor an immediate sale of shares.
• The derivative entries represent option-like awards that require future vesting and, for exercise, payment of the exercise price (here set at 110% of the grant-day close). RSUs convert to shares as they vest.
• Such grants are common executive compensation and should be interpreted as part of pay structure rather than a direct signal of short-term trading intent.